Dietary Supplementation of Fructooligosaccharides Reduces Hepatic Steatosis Associated with Insulin Resistance in Obese Zucker Rats
DOI:
https://doi.org/10.31989/ffhd.v1i5.130Abstract
Background: One in five adults in the United States is obese as defined by a body mass index of 30 kg/m2. Obesity is associated with metabolic syndrome, a combination of medical conditions including cardiovascular disease, type 2 diabetes, hypertension, hypercholesterolemia, and hypertriglyceridemia. These conditions present challenges to the medical care system and require a multifaceted approach through a variety of interventions. This study investigated the effects of fructooligosaccharides (FOS) at the level of 5 % (w/w) in alleviating the complications associated with metabolic syndrome.
Methods: The study was carried out using thirty-six, three-month old female lean and obese Zucker rats housed in an environmentally controlled laboratory. The Zucker rats were divided into three groups (N=12): Lean (L-CTRL) and obese controls (O-CTRL) and obese-FOS (O-FOS). The controls received AIN-93M purified rodent diet and the animals in the O-FOS group were fed AIN-93M diet modified to contain 5.0% FOS (w/w). After 100 days of treatment, the rats were fasted for 12 hours and sacrificed. Tissue and organs of interest, and blood were collected for analysis. Serum concentrations of the following were determined: glucose, glycosylated hemoglobin (HbA1c), total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), triglycerides (TG), and insulin. Gravimetric quantification of liver lipids was performed and peroxisome proliferator-activated receptor-γ (PPAR-γ) gene expression was determined in white adipose tissue by qRT-PCR.
Results: No significant differences were observed in the serum lipids, fasting blood glucose, HbA1c and PPAR-γ gene expression in white adipose tissue of O-FOS group compared to O-CTRL group. FOS supplementation significantly lowered the percent total liver lipids by 12% with a subsequent reduction in the liver weights compared to O-CTRL rats. Serum insulin concentrations were lowered 3.6 fold in O-FOS group compared to O-CTRL (P < 0.05).
Conclusion: Based on these findings we conclude that dietary supplementation of 5% FOS (w/w) may reduce hepatic steatosis and the risk for non-alcoholic fatty liver disease (NAFLD) associated with insulin resistance without changes in blood lipids and glucose levels.
Key words: Dietary fiber, Fructooligosaccharide, Hepatosteatosis, Liver lipids, Non-alcoholic fatty liver disease (NAFLD), Zucker.
Downloads
Published
Issue
Section
License
Any manuscripts or substantial parts of it, submitted to the journal must not be under consideration by or previously published in any other journal or citable form. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights or the rights of a third party. In submitting one's article in any form, the author has assigned the FFC publishing rights and has agreed to an automatic transfer of the copyright to the publisher. This is so that the FFC may create print option journals, for example, at the FFC’s discretion. If the author wishes to distribute their works by means outside of the FFC, for example within their community, they will have to place a request.
Correspondence concerning articles published in Functional Foods in Health and Disease is encouraged. While derivative works (adaptations, extensions on the current work, etc.) are allowed, distribution of the modified material is not allowed without permission from the FFC.